Alimenté par : Claudia (ADFI Alsace), Gaëlle (ADFI), Isabelle, Maïlé Onfray

Cet outil s'appuie sur PubMind

Un accès direct à la littérature scientifique via la base PubMed permettant de faciliter la veille sur les enjeux complexes de la santé mentale et du fait religieux : de la neuroscience des croyances à l'étude des abus spirituels, en passant par la prise en charge des traumatismes et des processus de déconversion.

Dernière synchronisation le 01/09/2026

Thérapies de Conversion

Pratiques visant à modifier l'orientation sexuelle ou l'identité de genre, illégales en France depuis la loi n°2022-92, et leurs effets psychologiques documentés.

500 articles disponibles

conversion therapy
sexual orientation change effort
SOCE harm
gender identity conversion
reparative therapy mental health
ex-gay therapy
conversion practice religious

Apparent Long-Term Cure Following Conversion Therapy for Initially Unresectable Pancreatic Ductal Adenocarcinoma: A Case Report.

Locally advanced pancreatic ductal adenocarcinoma (LA-PDAC) is increasingly managed with neoadjuvant chemotherapy with the aim of tumour downstaging and potential conversion to resection. LA-PDAC is t…

Thérapies de Conversion
Florou, E., Zen, Y., Srinivasan, P., & Prachalias, A. (2026). Apparent Long-Term Cure Following Conversion Therapy for Initially Unresectable Pancreatic Ductal Adenocarcinoma: A Case Report.. Cureus, 18(3), e105912. https://doi.org/10.7759/cureus.105912
01/03/2026 Lire →

Conversion therapy for advanced hepatocellular carcinoma following complete response to transarterial radioembolization combined with atezolizumab and bevacizumab.

BACKGROUND: The current Barcelona Clinic Liver Cancer (BCLC) classification recommends systemic treatment with atezolizumab and bevacizumab as the first-line therapy for advanced hepatocellular carcin…

Thérapies de Conversion
Popovic, P., Kalamutova, A., Djokic, M., Cuderman, A., Boltezar, G., & Trotovsek, B. (2026). Conversion therapy for advanced hepatocellular carcinoma following complete response to transarterial radioembolization combined with atezolizumab and bevacizumab.. Radiol Oncol, 60(1), 40-48. https://doi.org/10.2478/raon-2026-0015
01/03/2026 Lire →

Conversion Therapy for cT4b and M1 Esophageal Squamous Cell Carcinoma: A Comprehensive Systematic Review.

Conversion therapy, defined as curative-intent surgery or chemoradiotherapy after induction therapy, is gaining attention in patients with initially unresectable esophageal squamous cell carcinoma due…

Thérapies de Conversion
Booka, E., & Takeuchi, H. (2026). Conversion Therapy for cT4b and M1 Esophageal Squamous Cell Carcinoma: A Comprehensive Systematic Review.. Ann Gastroenterol Surg, 10(2), 294-304. https://doi.org/10.1002/ags3.70104
01/03/2026 Lire →

Chemotherapy combined with pembrolizumab in advanced gallbladder cancer with subsequent radical resection: A case report.

Gallbladder cancer is often diagnosed at an advanced stage, preventing radical surgical intervention. Combined with its highly aggressive nature, this results in a generally poor prognosis. Although a…

Thérapies de Conversion
Hu, Y., Wei, Y., Liu, X., Shen, L., Wang, Y., & Yuan, J. (2026). Chemotherapy combined with pembrolizumab in advanced gallbladder cancer with subsequent radical resection: A case report.. ILIVER, 5(1), 100219. https://doi.org/10.1016/j.iliver.2026.100219
01/03/2026 Lire →

A novel triple-modality approach overcoming prohibitive hepatopulmonary shunt (HPS): Enabling yttrium-90 selective internal radiation therapy (Y90-SIRT) and subsequent curative resection in massive hepatocellular carcinoma (HCC).

Elevated hepatopulmonary shunt exceeding 20% is a strict contraindication for Y90-SIRT due to the risk of fatal radiation pneumonitis, posing a significant clinical challenge in the management of such…

Thérapies de Conversion
Luo, Y., & Lin, Y. (2026). A novel triple-modality approach overcoming prohibitive hepatopulmonary shunt (HPS): Enabling yttrium-90 selective internal radiation therapy (Y90-SIRT) and subsequent curative resection in massive hepatocellular carcinoma (HCC).. Radiol Case Rep, 21(3), 1099-1103. https://doi.org/10.1016/j.radcr.2025.11.007
01/03/2026 Lire →

Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy.

BACKGROUND AND AIMS: Pathological complete response (pCR) following conversion therapy for initially unresectable hepatocellular carcinoma (uHCC) remains challenging to predict preoperatively. This st…

Thérapies de Conversion
Zhou, S. Q., Wang, L. N., Wu, L. F., Sun, L. Y., Yang, Y. C., Yang, Z. Y., Wang, Z. Y., He, T., Li, F., Chen, L. L., Li, H., Zhu, X. D., Shen, Y. H., Huang, C., Ji, Y., Gao, Q., Zhou, J., Fan, J., Chen, Y. J., … China, L. i. v. e. r. . C. a. n. c. e. r. . S. t. u. d. y. . G. r. o. u. p. . Y. o. u. n. g. . I. n. v. e. s. t. i. g. a. t. o. r. s. . (. C. L. E. A. P. ). (2026). Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy.. Hepatology. https://doi.org/10.1097/HEP.0000000000001724
26/02/2026 Lire →

Survival Outcomes, Recurrence Patterns, and Its Corresponding Therapeutic Management after Conversion Therapy Followed by Curative Resection for Hepatocellular Carcinoma: A Real-World Study.

INTRODUCTION: There remains a scarcity of research focusing on long-term survival, the administration of adjuvant therapy, and recurrence following conversion resection in patients suffering from init…

Thérapies de Conversion
Xiao, R., Yang, Z., Zheng, Z., Liu, N., Yu, W., Lin, Q., Chen, J., Wang, J., Zhou, Z., Zhang, Y., Chen, M., & Hu, D. (2026). Survival Outcomes, Recurrence Patterns, and Its Corresponding Therapeutic Management after Conversion Therapy Followed by Curative Resection for Hepatocellular Carcinoma: A Real-World Study.. Liver Cancer. https://doi.org/10.1159/000550954
23/02/2026 Lire →

Prognostic outcomes of surgery vs. non-surgery in initially unresectable HCC with successful conversion via ICI + TKI therapy.

BACKGROUND: No consensus exists on optimal post-conversion therapy for initially unresectable hepatocellular carcinoma (uHCC) patients responding to a combination of immune checkpoint inhibitors (ICIs…

Thérapies de Conversion
Sun, Z., Wang, Y., Tan, Z., Zhou, J., Chen, X., Li, O., & Peng, C. (2026). Prognostic outcomes of surgery vs. non-surgery in initially unresectable HCC with successful conversion via ICI + TKI therapy.. BMC Gastroenterol, 26(1). https://doi.org/10.1186/s12876-026-04677-w
13/02/2026 Lire →

[Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China(2026 edition)].

Hepatocellular carcinoma with portal vein tumor thrombus (PVTT) has a high incidence and an extremely poor prognosis. Current international guidelines still exhibit discrepancies in the diagnosis and …

Thérapies de Conversion
Chinese, A. s. s. o. c. i. a. t. i. o. n. . o. f. . L. i. v. e. r. . C. a. n. c. e. r. . a. n. d. . C. h. i. n. e. s. e. . M. e. d. i. c. a. l. . D. o. c. t. o. r. . A. s. s. o. c. i. a. t. i. o. n. (2026). [Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China(2026 edition)].. Zhonghua Yi Xue Za Zhi, 106, 41-55. https://doi.org/10.3760/cma.j.cn112137-20251211-03271
12/02/2026 Lire →

Addressing the missing stair: Conversion culture in mental health ecosystems.

The author wants to direct attention to the persistent otherisation of queer/trans people in mental health ecosystems that breeds conversion culture ‒ a system of values that looks at gender/sexual di…

Thérapies de Conversion
Chatterjee, A. (2026). Addressing the missing stair: Conversion culture in mental health ecosystems.. Indian J Med Ethics. https://doi.org/10.20529/IJME.2026.006
05/02/2026 Lire →

Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring.

PURPOSE: The optimal conversion treatment for patients with borderline resectable pancreatic cancer or locally advanced pancreatic cancer (BRPC/LAPC) remains unclear. In this study, we present the eff…

Thérapies de Conversion
Ni, J., Sun, Y., Cheng, H., Bai, X., Tong, F., Zhang, X., Wang, X., Mao, L., Li, G., Shen, S., Kong, W., He, J., Li, A., Chen, J., Tang, M., Chen, B., Li, Q., Gu, Q., Lu, Z., … Du, J. (2026). Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring.. Clin Cancer Res, 32(3), 516-527. https://doi.org/10.1158/1078-0432.CCR-25-2461
04/02/2026 Lire →

How to Integrate Surgery into the Multidisciplinary Treatment of Liver-Only Metastatic Colorectal Cancer.

Colorectal liver metastases (CRLM) represent a major determinant of prognosis in patients with metastatic colorectal cancer and account for a substantial proportion of cancer-related mortality worldw…

Thérapies de Conversion
Pérez-Santiago, L., Huntley, P. a. s. c. u. a. l. . D., Sánchez, L. a. r. a. . J. S., Huerta, M., & Dorcaratto, D. (2026). How to Integrate Surgery into the Multidisciplinary Treatment of Liver-Only Metastatic Colorectal Cancer.. Cancers (Basel), 18(3). https://doi.org/10.3390/cancers18030489
02/02/2026 Lire →